NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

NCT02913456

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Countries: Austria, Bulgaria, Italy, Portugal, Romania

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

\- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time

Exclusion Criteria:

\- Not applicable

Locations (54)

Graz, Austria
Graz, Austria
Klagenfurt, Austria
Leoben, Austria
Linz, Austria
Ried-innkreis, Austria
Vienna, Austria
Vienna, Austria
Vienna, Austria
Villach, Austria
Wiener Neustadt, Austria
Plovdiv, Bulgaria
Plovdiv, Bulgaria
Rousse, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Stara Zagora, Bulgaria
Varna, Bulgaria
Vratsa, Bulgaria
Bari, Apulia, Italy
Barletta, Apulia, Italy
Modena, Emilia-Romagna, Italy
Aviano (PN), Friuli Venezia Giulia, Italy
Latina, Lazio, Italy
Sora, Lazio, Italy
Viterbo, Lazio, Italy
Brescia, Lombardy, Italy
+ 24 more on CT.gov